Open AccessImmunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure
Author(s) -
SantanaDavila Rafael,
Rodriguez Cristina P.
Publication year - 2018
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2017-0527
Subject(s) - pembrolizumab , nivolumab , medicine , head and neck cancer , head and neck , immunotherapy , oncology , cancer , squamous cell cancer , intensive care medicine , surgery
The FDA‐approved immune checkpoint inhibitors, nivolumab and pembrolizumab, are the most recent biological therapies in the therapeutic armamentarium for recurrent metastatic head and neck squamous cell carcinomas. This article highlights the tools for analyzing the costeffectiveness of such therapies.